GERN News and Press, Geron Corporation From 05/02/24

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelsta...

2024-05-01 16:23:58 ET Summary Geron Corporation has a PDUFA date of June 16th of 2024 for the FDA to decide upon whether imetelstat should be approved for patients with low-risk myelodysplastic syndrome. The FDA Oncologic Drugs Advisory Committee already voted in favor of imetels...

2024-05-01 11:38:49 ET More on Geron Considering The Merits Of A Gamble On Geron Corporation Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA Baird downgrades...

2024-04-30 13:42:09 ET More on Geron Considering The Merits Of A Gamble On Geron Corporation Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA TD Cowen starts ...

2024-04-29 15:07:00 ET More on Geron Considering The Merits Of A Gamble On Geron Corporation Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA Geron announces ...

2024-04-28 04:39:02 ET Summary Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presented in the paragraphs below. Today, we...

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Companyȁ...

2024-04-11 15:56:04 ET Summary The FDA advisory committee voted 12-2 in favor of imetelstat's clinical profile in lower-risk myelodysplastic syndromes. The PDUFA target date for GERN's imetelstat NDA is June 16, 2024. An interim analysis in GERN's IMpactMF study in myelofibros...

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences: 23 rd Annual Needham Virtual Health...